Company & Sponsor Intelligence
Weill Medical College of Cornell University
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting1
Completed1
Countries1
Therapeutic footprint
depression
Indexed studies
NCT00601055Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease
depression · United StatesNA
depression · United StatesNA
NCT03649724The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT02292849Peer to Peer Delivery of Behavioral Activation
depression · United StatesNA
depression · United StatesNA
NCT05183230WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt
depression · United StatesNA
depression · United StatesNA
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →